See more : TVS Motor Company Limited (TVSMOTOR.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Humanigen, Inc. (HGEN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Humanigen, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- ITAB Shop Concept AB (publ) (ITAB.ST) Income Statement Analysis – Financial Results
- HANMI Semiconductor Co., Ltd. (042700.KS) Income Statement Analysis – Financial Results
- Jai Corp Limited (JAICORPLTD.NS) Income Statement Analysis – Financial Results
- KalNorth Gold Mines Limited (CKGDF) Income Statement Analysis – Financial Results
- Mobile Global Esports Inc. (MGAM) Income Statement Analysis – Financial Results
Humanigen, Inc. (HGEN)
About Humanigen, Inc.
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called 'cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is also being studied in conjunction with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1. Ifabotuzumab has been evaluated in a Phase 1 study of glioblastoma multiforme that showed tumor specific targeting of all known tumor sites with no normal tissue uptake. HGEN005 is being explored as a treatment for a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.51M | 3.60M | 312.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 44.00K | 6.10M | 20.26M | 17.71M | 589.00K |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.51M | 3.60M | 312.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 44.00K | 6.10M | 20.26M | 17.71M | 589.00K |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 55.21M | 213.12M | 72.71M | 2.62M | 2.22M | 11.17M | 10.45M | 16.72M | 26.57M | 32.64M | 24.52M | 18.51M | 18.89M | 22.86M |
| General & Administrative | 15.61M | 23.25M | 15.80M | 6.33M | 9.11M | 7.87M | 8.38M | 14.30M | 10.15M | 8.31M | 5.06M | 4.01M | 4.94M | 5.19M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.61M | 23.25M | 15.80M | 6.33M | 9.11M | 7.87M | 8.38M | 14.30M | 10.15M | 8.31M | 5.06M | 4.01M | 4.94M | 5.19M |
| Other Expenses | 0.00 | -1.61M | -1.00K | -1.00K | 324.00K | 431.00K | 125.00K | -213.00K | -154.00K | -39.00K | 113.00K | -8.00K | 915.00K | 348.00K |
| Operating Expenses | 70.82M | 236.37M | 88.51M | 8.94M | 11.33M | 19.03M | 18.83M | 31.02M | 36.72M | 40.95M | 29.58M | 22.52M | 23.84M | 28.05M |
| Cost & Expenses | 70.82M | 236.37M | 88.51M | 8.94M | 11.33M | 19.03M | 18.83M | 31.02M | 36.72M | 40.95M | 29.58M | 22.52M | 23.84M | 28.05M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.00K | 88.00K | 86.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.92M | 2.26M | 1.34M | 1.35M | 852.00K | 3.06M | 131.00K | 842.00K | 1.21M | 1.09M | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 492.00K | -1.61M | -1.00K | -1.00K | 19.00K | 48.00K | 102.00K | 197.00K | 310.00K | 298.00K | 304.00K | 595.00K | 843.00K | 844.00K |
| EBITDA | -67.81M | -234.39M | -88.20M | -8.95M | -10.99M | -18.55M | -18.60M | -31.00M | -36.47M | -40.56M | -23.18M | -1.67M | -5.28M | -26.62M |
| EBITDA Ratio | -2,697.37% | -6,519.75% | -28,268.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -92,190.91% | -380.09% | -8.25% | -29.81% | -4,519.35% |
| Operating Income | -68.30M | -232.77M | -88.20M | -8.94M | -11.33M | -19.03M | -18.83M | -34.35M | -36.72M | -40.91M | -23.48M | -2.27M | -6.12M | -27.46M |
| Operating Income Ratio | -2,716.95% | -6,474.88% | -28,268.59% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -92,975.00% | -385.08% | -11.19% | -34.57% | -4,662.65% |
| Total Other Income/Expenses | -2.43M | -3.88M | -1.34M | -1.35M | -673.00K | -2.96M | -8.19M | -1.03M | -1.28M | -1.04M | -27.00K | 35.00K | 1.02M | 639.00K |
| Income Before Tax | -70.73M | -236.65M | -89.54M | -10.29M | -12.00M | -21.99M | -27.02M | -35.38M | -38.00M | -41.95M | -23.51M | -2.23M | -5.10M | -26.82M |
| Income Before Tax Ratio | -2,813.44% | -6,582.73% | -28,697.12% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -95,336.36% | -385.52% | -11.02% | -28.79% | -4,554.16% |
| Income Tax Expense | -492.00K | 2.26M | 1.34M | 1.35M | 179.00K | 3.49M | 256.00K | 629.00K | 1.06M | 1.05M | 140.00K | -43.00K | -108.00K | -19.00K |
| Net Income | -70.24M | -238.91M | -90.87M | -11.64M | -12.00M | -21.99M | -27.02M | -35.38M | -38.00M | -41.95M | -23.51M | -2.23M | -5.10M | -26.81M |
| Net Income Ratio | -2,793.87% | -6,645.70% | -29,125.32% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -95,336.36% | -385.52% | -11.02% | -28.79% | -4,550.93% |
| EPS | -1.18 | -4.08 | -2.46 | -0.52 | -0.63 | -7.34 | -13.92 | -42.88 | -46.09 | -69.13 | -448.66 | -46.17 | -97.33 | -85.16 |
| EPS Diluted | -1.18 | -4.08 | -2.46 | -0.52 | -0.63 | -7.34 | -13.92 | -42.88 | -46.09 | -69.13 | -448.66 | -46.17 | -97.33 | -85.16 |
| Weighted Avg Shares Out | 59.49M | 58.53M | 36.96M | 22.36M | 18.95M | 3.00M | 1.94M | 825.00K | 824.48K | 606.76K | 52.40K | 48.34K | 52.40K | 314.77K |
| Weighted Avg Shares Out (Dil) | 59.49M | 58.53M | 36.96M | 22.36M | 18.95M | 3.00M | 1.94M | 825.00K | 824.48K | 606.76K | 52.40K | 48.34K | 52.40K | 314.77K |
Levi & Korsinsky, LLP Notifies Shareholders of Humanigen, Inc. (HGEN) an Upcoming Claims Deadline in a Class Action Settlement
Levi & Korsinsky, LLP Notifies Shareholders of Humanigen, Inc. (HGEN) an Upcoming Claims Deadline in a Class Action Settlement
HGEN Stock Alert: Why Humanigen Just Filed for Ch. 11 Bankruptcy
COVID-19 treatment developer Humanigen files for Chapter 11 bankruptcy
Humanigen Announces First Participant Dosed in RATinG Trial of Lenzilumab for Early Treatment of Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation
Humanigen stock removed from S&P Total Market Index as firm faces bankruptcy
Why Is Humanigen (HGEN) Stock Down 72% Today?
Humanigen Presents Promising New Hematologic Data from PREACH-M Trial for Chronic Myelomonocytic Leukemia Treatment at the 2023 European Hematology Association Congress
Humanigen (HGEN) Surges on Lenzilumab Study Data for Leukemia
3 Hot Penny Stocks To Watch Today; Is It Time To Buy?
Source: https://incomestatements.info
Category: Stock Reports